Clinical Trial

Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 14, 2025 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase I clinical study of HS-20093. The purpose of this study is to evaluate the safety, tolerability, PK and efficacy of HS-20093 in combination with Adebrelimab in patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC).
Trial Details
NCT Number NCT07063407
Lead Sponsor Shanghai Hansoh Biomedical Co., Ltd
Conditions Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Enrollment 50 participants
Start Date 2025-07-31
Primary Completion 2026-04-30 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-14